Rad Tech CE, ASRT, ARRT® CE, Category A Credits | Radiology Continuing Education

Approvals/Requirements Satisfied by eRADIMAGING Courses

  • ASRT approval for ARRT Category A credit
  • All Courses eligible of international radiographers' CPD requirements
  • ASRT and MDCB are approved continuing education providers of ARRT and all courses are accepted by ARRT
  • California CE requirements met for all radiography courses
  • NMTCB accepted (All Courses)
  • All Courses available for RRAs
  • ARMRIT accepted (All MRI Courses)
  • MDCB approval by the Medical Dosimetrist Certification (Selected Courses)
  • Florida approval for all courses 1 credit or more
  • ARDMS accepted (All Courses)
  • CAMRT and Sonography Canada recognize the ASRT approval (All Courses)
  • Approval: This course is approved by ASRT - an approved continuing education provider of ARRT.
  • Release Date: 11/15/2018
  • Expiration Date: 12/1/2021
  • Credit Hours: 1 Credit
  • ACCME Approval: This course is approved by the ACCME. (Release Date: 11/15/2018  Expiration Date: 11/15/2020)

The Role of Theranostics in Nuclear Medicine: Cancer Diagnosis and Management

Steven Marks*

*President, MedCom Consultants, Inc, Potomac MD

Address correspondence to: Steven Marks, MedCom Consultants Inc, 1311 Fallsmead Way, Potomac MD 20854. Email: steven.marks52@gmail.com.

Disclosure statement: The author reports having no financial or advisory relationship with any corporate, medical, or political organization doing work related to this paper or other business activity at MedCom Consultants, Inc.

AKH Inc. planners and reviewers have no relevant financial relationships to disclose.



Precision therapy in cancer is critical to the delivery of safe and efficacious care. Radiotheranostics, a novel approach in nuclear medicine that combines imaging and therapeutics, has become an invaluable way to personalize the diagnosis and treatment of patients with neoplastic diseases. Theranostics provides a platform for identifying the biologic targets of the disease process and the patients who will benefit most from the use of radionuclide agents. This approach can predict response and risk of toxicity, and can monitor the course of therapy. Since the introduction of the first agent, radioiodine, in 1941, the number and types of radiotheranostic agents under investigation and in clinical use have burgeoned. Newer isotopes, which include radiolabeled somatostatin receptor analogs for neuroendocrine tumors, prostate-specific membrane antigen in prostate cancer, and chemokine receptors in multiple myeloma, have yielded promising results in clinical studies; further research is underway on these and other molecular targets, as well as on the use of high-energy alpha particles for the treatment of disseminated residual tumors. As new agents emerge, questions regarding regulatory approval and reimbursement will need to be addressed, so these important treatments can assume their proper place in the armamentarium of cancer diagnosis and management.

View the full content

Sample eRADIMAGING Course *

* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.

Become a member

Satisfy your CE requirements today!

Join now

We offer special group rates, call or email.




Enter your email address to receive our new course alerts.